DC Chemicals Limited
China
Product Name: Furegrelate sodium
Price:
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

85666-17-7

85666-17-7 structure

Name: Furegrelate sodium
Chemical Name: furegrelate sodium
CAS Number: 85666-17-7
Molecular Formula: C₁₅H₁₀NNaO₃
Molecular Weight: 275.235
Catalog: Research Areas Cardiovascular Disease
Create Date: 2017-09-10 23:20:57
Modify Date: 2024-01-06 01:54:59
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent[1][2].

Name	furegrelate sodium
Synonyms	Sodium 5-(pyridin-3-ylmethyl)-1-benzofuran-2-carboxylate Sodium p-Styrenesulfonate 4-Vinylbenzenesulfonic acid sodium salt sodium styrene sulphonate p-styrenesulfonic acid sodium salt sodium styrene sulfonate sodium styrene-4-sulphonate Sodium 5-(3-pyridinylmethyl)-1-benzofuran-2-carboxylate Styrene-4-sulfonic acid sodium salt 5-(3-Pyridinylmethyl)-2-benzofurancarboxylic Acid Sodium Salt 2-Benzofurancarboxylic acid, 5-(3-pyridinylmethyl)-, sodium salt (1:1) sodium 4-styrenesulfonate Sodium 4-vinylbenzenesulfonate

Description	Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others
In Vivo	Furegrelate Sodium (U-63557A) (1-5 mg/kg; Oral) prevents blockage of the coronary artery[1]. Furegrelate Sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation[1]. Furegrelate Sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature[2]. Furegrelate also is orally available, has a long half-life of 4.2–5.8 hours in adult humans (compared to several other therapies for PAH including nitric oxide and prostacyclin analogs), and reportedly is highly specific for its target enzyme[2]. Animal Model: Mongrel dogs (19-30 kg)[1] Dosage: 1-5 mg/kg Administration: Oral (via a gastric tube) Result: Prevented blockage of the coronary artery.
References	[1]. Gorman RR, et al. Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate. Prostaglandins. 1983 Aug;26(2):325-42. [2]. Hirenallur-S DK, et al. Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. Pulm Circ. 2012 Apr-Jun;2(2):193-200.

Boiling Point	458.7ºC at 760 mmHg
Molecular Formula	C₁₅H₁₀NNaO₃
Molecular Weight	275.235
Flash Point	231.2ºC
Exact Mass	275.055847
PSA	66.16000
LogP	1.78210